Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$16.22 USD
+0.28 (1.76%)
Updated May 13, 2024 04:00 PM ET
After-Market: $16.23 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CPRX 16.22 +0.28(1.76%)
Will CPRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for CPRX
Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Truist Financial Keeps Their Buy Rating on Catalyst Pharma (CPRX)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
Catalyst Pharmaceuticals price target raised by $2 at H.C. Wainwright, here's why